Zymeworks Inc (ZYME) Stock Price, Quote & News

Company Profile

Zymeworks Inc., a clinical-stage biotechnology company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer, and autoimmune and inflammatory diseases (AIID). Its therapeutic platforms and fully integrated drug development engine provides the flexibility and compatibility to precisely engineer and develop highly differentiated antibody-based therapeutic candidates. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform in...

Industry: Biotechnology

Sector: Healthcare

Phone: 302 274 8744

Website: www.zymeworks.com

Address:

108 Patriot Drive, Suite A, Middletown, United States

maplelakeduckslayer Jul. 17 at 2:27 PM

$ZYME this is starting to squeeze shorts a bit they shorted 3 million shares under $13 and there's zero supply available here. One nugget at earnings this can be at new 52 week highs

1 · Reply

SKL05 Jul. 17 at 2:17 PM

$ZYME something's cookin'

0 · Reply

Doozio Jul. 10 at 5:01 PM

$INCY that $ZYME is $NOW a Thursday 🐑 🎁 in $RYTM 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jul. 10 at 5:00 PM

On FRYday da 🧠 shall enter its $PRIM 🐒🍌 $GENI us $ZYME ♾️

0 · Reply

tdntdn Jul. 9 at 11:15 PM

$ZYME wish there was more volume

1 · Reply

topstockalerts Jul. 4 at 7:06 PM

$ZYME next week will be fun 🏦🍾🚨

1 · Reply

Doozio Jul. 4 at 5:20 PM

$INCY everything happens wen it’s $ZYME. Out of the tightness as NVDA is leading during 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jul. 4 at 5:17 PM

$CGEN not that TME. But this $ZYME it’s out of the tightness 🐒🍌🧠⏰♾️

1 · Reply

Boris_Badenov Jul. 4 at 8:01 AM

$ZYME Ziihera approved in Europe. https://www.thepharmaletter.com/biotechnology/ec-approves-jazzs-ziihera-in-biliary-tract-cancer

1 · Reply

JarvisFlow Jul. 3 at 11:00 AM

HC Wainwright & Co. has updated their rating for Zymeworks ( $ZYME ) to Neutral with a price target of 13.

2 · Reply

Zymeworks to Report Second Quarter 2025 Financial Results and Host Conference Call on August 7, 2025

Jun 12, 2025, 4:34 PM EDT - 4 weeks ago

Zymeworks: Early-Stage Biotech Feel Despite Zanidatamab Advancements (Downgrade)

May 30, 2025, 6:00 AM EDT - 6 weeks ago

Zymeworks Announces NMPA Approval of Zanidatamab in China for Adults with Previously Treated, Unresectable or Metastatic HER2-high expression (IHC3+) Biliary Tract Cancer

May 22, 2025, 5:00 PM EDT - 7 weeks ago

Zymeworks Announces Presentations Highlighting Breadth of Oncology Portfolio at Upcoming Medical Conferences

May 21, 2025, 6:00 AM EDT - 2 months ago

Zymeworks Announces Participation in Upcoming Investor Conferences

May 19, 2025, 4:15 PM EDT - 2 months ago

Zymeworks Presents Preclinical Data on ZW1528 at the American Thoracic Society International Conference

May 8, 2025, 11:00 PM EDT - 2 months ago

Zymeworks Inc. (ZYME) Q1 2025 Earnings Call Transcript

May 8, 2025, 4:05 PM EDT - 2 months ago

Zymeworks Provides Corporate Update and Reports First Quarter 2025 Financial Results

Apr 28, 2025, 5:33 PM EDT - 2 months ago

Zymeworks: A Strong Buy With Newly-Approved Cancer Drug, Excellent Financials, And Expansive Pipeline

Apr 28, 2025, 10:48 AM EDT - 2 months ago

Zymeworks: Poised For Growth With Platform Validation

Apr 25, 2025, 1:00 PM EDT - 2 months ago

Zymeworks Presents New Data from Multiple Development Programs at 2025 AACR Annual Meeting

Apr 21, 2025, 6:00 AM EDT - 3 months ago

Zymeworks Appoints Dr. Sabeen Mekan as Senior Vice President, Clinical Development

Apr 17, 2025, 6:00 AM EDT - 3 months ago

Zymeworks to Report First Quarter 2025 Financial Results and Host Conference Call on May 8, 2025

Mar 25, 2025, 4:30 PM EDT - 4 months ago

Zymeworks to Present Preclinical Data on T cell Engager and Antibody-Drug Conjugate Platforms in Six Posters at AACR Annual Meeting

Mar 6, 2025, 1:18 PM EST - 4 months ago

Cancer-Focused Zymeworks' Q4 Earnings Miss Expectations, Reprioritize Resources To Focus On ZW251

Mar 5, 2025, 8:43 PM EST - 4 months ago

Zymeworks Inc. (ZYME) Q4 2024 Earnings Call Transcript

Mar 5, 2025, 4:05 PM EST - 4 months ago

Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2024 Financial Results

Feb 26, 2025, 6:00 AM EST - 5 months ago

Zymeworks Announces Achievement of $14 Million Milestone from GSK Collaboration

Feb 18, 2025, 6:00 AM EST - 5 months ago

Zymeworks Announces Appointment of Oleg Nodelman to Board of Directors

Feb 13, 2025, 6:00 AM EST - 5 months ago

Zymeworks To Report Fourth Quarter and Full Year 2024 Financial Results and Host Conference Call on March 5, 2025

Jan 22, 2025, 12:29 PM EST - 6 months ago

3 Biotech Stocks With Notable Insider Buying

AUPH AZN COGT JAZZ ONC XBI

Jan 8, 2025, 4:05 PM EST - 6 months ago

Zymeworks Outlines Strategic Priorities and Outlook for 2025 and 2026

Dec 19, 2024, 9:00 AM EST - 7 months ago

Zymeworks: Prime Time For Ziihera, Early-Stage Pipeline Progressing Ahead Of Schedule

Nov 21, 2024, 6:00 AM EST - 8 months ago

FDA Grants U.S. Approval of Ziihera® (zanidatamab-hrii) for the Treatment of Adults with Previously Treated, Unresectable or Metastatic HER2-positive (IHC 3+) Biliary Tract Cancer (BTC)

Nov 5, 2024, 6:00 AM EST - 9 months ago

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW191 in Folate Receptor-⍺ Expressing Advanced Solid Tumors

Nov 4, 2024, 4:28 AM EST - 9 months ago

Zymeworks: Turning The Tide With 2 Key Milestones For Zanidatamab

Oct 31, 2024, 10:05 PM EDT - 9 months ago

Zymeworks Inc. (ZYME) Q3 2024 Earnings Call Transcript

Oct 25, 2024, 6:00 AM EDT - 9 months ago

Zymeworks Presents New Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Oct 21, 2024, 6:00 AM EDT - 9 months ago

Zymeworks Announces First Patient Dosed in Phase 1 Clinical Trial Evaluating ZW171 in Advanced Mesothelin-Expressing Cancers

Oct 10, 2024, 6:30 AM EDT - 10 months ago

Zymeworks to Report Third Quarter 2024 Financial Results and Host Conference Call on October 31, 2024

Sep 27, 2024, 2:47 PM EDT - 10 months ago

Zymeworks Approaching A Moment Of Truth With Zanidatamab

Sep 18, 2024, 6:00 AM EDT - 10 months ago

Zymeworks to Present Preclinical Data on Antibody-Drug Conjugate Programs at EORTC-NCI-AACR Conference

Sep 3, 2024, 4:30 PM EDT - 11 months ago

Zymeworks Reports Inducement Grant Under Nasdaq Stock Market Rule 5635(c)

Aug 1, 2024, 10:58 PM EDT - 1 year ago

Zymeworks Inc. (ZYME) Q2 2024 Earnings Call Transcript

Aug 1, 2024, 4:10 PM EDT - 1 year ago

Zymeworks Announces Share Repurchase Program of up to $60 Million of its Common Stock

Jul 25, 2024, 4:30 PM EDT - 1 year ago

Zymeworks Appoints Leone Patterson as Chief Business and Financial Officer

Jul 22, 2024, 6:00 AM EDT - 1 year ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW191, a Novel Folate Receptor-⍺ Targeted Topoisomerase I Inhibitor Antibody-Drug Conjugate

Jul 11, 2024, 6:30 AM EDT - 1 year ago

Zymeworks To Report Second Quarter 2024 Financial Results and Host Conference Call on August 1, 2024

Jun 17, 2024, 6:00 AM EDT - 1 year ago

Zymeworks Announces FDA Clearance of Investigational New Drug Application for ZW171, a novel 2+1 T-cell Targeting Bispecific Antibody for Mesothelin-expressing Cancers

Jun 10, 2024, 6:00 AM EDT - 1 year ago

Zymeworks Announces China NMPA Acceptance of Biologics License Application for Zanidatamab for Second-Line Treatment of Biliary Tract Cancer

maplelakeduckslayer Jul. 17 at 2:27 PM

$ZYME this is starting to squeeze shorts a bit they shorted 3 million shares under $13 and there's zero supply available here. One nugget at earnings this can be at new 52 week highs

1 · Reply

SKL05 Jul. 17 at 2:17 PM

$ZYME something's cookin'

0 · Reply

Doozio Jul. 10 at 5:01 PM

$INCY that $ZYME is $NOW a Thursday 🐑 🎁 in $RYTM 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jul. 10 at 5:00 PM

On FRYday da 🧠 shall enter its $PRIM 🐒🍌 $GENI us $ZYME ♾️

0 · Reply

tdntdn Jul. 9 at 11:15 PM

$ZYME wish there was more volume

1 · Reply

topstockalerts Jul. 4 at 7:06 PM

$ZYME next week will be fun 🏦🍾🚨

1 · Reply

Doozio Jul. 4 at 5:20 PM

$INCY everything happens wen it’s $ZYME. Out of the tightness as NVDA is leading during 🐒🍌🧠⏰♾️

0 · Reply

Doozio Jul. 4 at 5:17 PM

$CGEN not that TME. But this $ZYME it’s out of the tightness 🐒🍌🧠⏰♾️

1 · Reply

Boris_Badenov Jul. 4 at 8:01 AM

$ZYME Ziihera approved in Europe. https://www.thepharmaletter.com/biotechnology/ec-approves-jazzs-ziihera-in-biliary-tract-cancer

1 · Reply

JarvisFlow Jul. 3 at 11:00 AM

HC Wainwright & Co. has updated their rating for Zymeworks ( $ZYME ) to Neutral with a price target of 13.

2 · Reply

maplelakeduckslayer Jun. 28 at 4:09 AM

$ZYME Management removed the 19.9% ownership provision on the warrant exercise with Ecor1 and they exercised in full. They now own a lil over 30% of the company...just under 23 mil shares

3 · Reply

jimmythetulip Jun. 25 at 2:50 PM

$ZYME is there any sort of news or catalyst expected anytime soon?

1 · Reply

Fast_Eddie_Felson Jun. 24 at 1:13 AM

$ZYME stock is a complete turd and just beholden to a Jazz buyout at this point. Wtf is ecor doing accumulating this 💩. Hasn’t done shit in years

0 · Reply

twitofstock Jun. 16 at 4:21 PM

$ZYME $JAZZ Just updated the primary completion for Herizon-gae-01 trial from 2025-05-15 to 2025-10-15 does this mean that Ziihera is more efficient than they anticipated?

1 · Reply

maplelakeduckslayer Jun. 11 at 9:40 PM

$ZYME Shorts shorted another 400k shares may 15-may31. 7.2 mil shares short on a stock that is 95% held only a few million shares freely trade. Chart is breaking over the descending trendline going back to November With lots of upcoming catalysts

0 · Reply

maplelakeduckslayer Jun. 9 at 10:48 PM

$ZYME several large orders intraday large short started covering before the next push

1 · Reply

jimmythetulip May. 30 at 2:13 PM

$ZYME typical. Goes down on good news.

3 · Reply

maplelakeduckslayer May. 30 at 1:30 PM

$ZYME Couple presentations coming up over the next month and EU approval should hit in june as well

1 · Reply

StocktwitsNews May. 30 at 11:54 AM

Zymeworks’ Drug Gets Conditional Approval For Biliary Tract Cancer Treatment In China: Retail Sentiment Refuses To Budge $ZYME $IWM $VTI https://stocktwits.com/news/equity/markets/zymeworks-drug-gets-conditional-approval-for-biliary-tract-cancer-in-china/ch0Mun4RbMx

0 · Reply

DonCorleone77 May. 30 at 11:20 AM

$ZYME Zymeworks announces NMPA approval of zanidatamab in China Zymeworks announced that the National Medical Products Administration in China has approved zanidatamab for the treatment of patients with previously treated, unresectable or metastatic HER2-positive biliary tract cancer. The conditional approval marks the first and only1 dual HER2-targeted bispecific antibody approved for HER2-high expression BTC in China. Zymeworks' collaboration partner, BeOne Medicines Ltd., obtained the conditional approval under the terms of its Asia Pacific license and collaboration agreement with Zymeworks. Continued approval of this indication will depend on the verification of clinical benefit in the patient population through ongoing confirmatory trials.

0 · Reply

Boris_Badenov May. 30 at 10:54 AM

$ZYME Zani approved in China for BTC. milestone payments and royalties to come. “$20 million milestone payment to be received from BeOne Medicines; Zymeworks remains eligible to receive up to $144 million in additional development and commercial milestones” ”Zymeworks is also eligible to receive tiered royalties of up to 19.5% of net sales in BeOne Medicine’s territories.” https://ir.zymeworks.com/news-releases/news-release-details/zymeworks-announces-nmpa-approval-zanidatamab-china-adults

1 · Reply

omiabtrades May. 29 at 10:44 AM

$ZYME Monthly - this one looks better if it can clear above the pink circle getting a nice close over that 16.85 - 17$ range https://www.tradingview.com/x/wj5wbc1g Doing that can lead it to test the blue arrow within that trading range if the circle , I like 25-30$ as a price target on this one

0 · Reply

Market Cap	897.52M
Revenue (ttm)	76.30M
Net Income (ttm)	-122.70M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-160.81%
Debt to Equity Ratio	0.00

Volume	347,329
Avg Vol	466,476
Day's Range	N/A - N/A
Shares Out	69.68M
Stochastic %K	73%
Beta	1.19
Analysts	Strong Sell
Price Target	$21.35